कंपनी का अवलोकन
Oscar Health, Inc. operates as a healthcare technology company within the United States, providing health plans to individuals, families, employees, and small group markets while offering platforms like +Oscar to empower others throughout the healthcare system. The firm functions in the Healthcare sector, specifically the Healthcare Plans industry, which implies a focus on insurance administration, network management, and digital health solutions rather than pharmaceutical manufacturing or medical device production. The company's market capitalization stands at $4.36B, and it generated annual revenue of $11.70B while employing 2305 staff members. These figures indicate that Oscar Health maintains a significant but mid-cap presence in the competitive health insurance landscape, with revenue levels suggesting substantial scale in acquiring and managing policyholders across various demographics. The employment count of 2305 reflects a workforce size consistent with a national technology-driven insurer, supporting extensive claims processing and customer service operations necessary to serve its diverse member base. The combination of a $11.70B revenue stream and a $4.36B market cap suggests the market values the company at approximately 37% of its annual sales, a metric often seen in capital-intensive or high-growth technology sectors where future scalability is priced more heavily than current profitability.
वित्तीय स्वास्थ्य
The company reported a trailing twelve-month revenue of $11.70B, yet it recorded a net income of -$443,151,008 and an EBITDA of -$367,464,992 during the same period. The substantial gap between the $11.70B revenue and the negative net income reveals a cost structure where operating expenses, including technology infrastructure and customer acquisition costs, significantly outpace gross margins, resulting in an operating loss. Despite these earnings losses, the company generated a positive free cash flow of $698.00M, which indicates a degree of financial flexibility allowing the firm to fund operations and potentially invest in growth initiatives without immediate reliance on external equity financing. The gross margin stands at 14.4%, indicating that for every dollar of premium revenue, the company retains $0.144 after direct medical costs. However, the operating margin is negative at -11.9%, and the profit margin is -3.8%, signaling that overhead and administrative expenses are consuming the majority of the gross profit, a common characteristic in the early stages of scaling digital health platforms. The balance sheet shows a cash position of $3.99B against total debt of $498.80M, while the debt-to-equity ratio is reported at 50.86, suggesting a capital structure that relies heavily on equity or carries significant leverage relative to book equity. The current ratio of 0.95 indicates that current assets are slightly lower than current liabilities, pointing to potential tightness in short-term liquidity that requires careful management of working capital. Furthermore, the return on equity is -44.4% and the return on assets is -4.4%, metrics that reveal that management is currently not generating positive returns on the capital invested by shareholders or held in assets, reflecting the net loss position.
मूल्यांकन आकलन
The trailing P/E ratio is listed as N/A due to the negative earnings, while the forward P/E is 10.88, implying that the market expects earnings to become positive in the future to justify the current stock price. The price-to-book ratio is 4.45, which indicates that the market is valuing the company at more than four times its net asset value, suggesting a premium placed on the intangible value of its technology platform and customer base. The price-to-sales ratio stands at 0.37, and the EV/EBITDA is -2.36; these alternative metrics suggest the market is pricing the stock based on revenue generation potential rather than current profitability, a typical valuation approach for high-growth healthcare technology firms. The stock has traded between a 52-week high of $23.80 and a 52-week low of $10.69, providing a clear range within which the current market price fluctuates based on sector sentiment. The beta value of 1.93 indicates that the stock is highly volatile and tends to move significantly more than the broader market, reflecting the inherent risks associated with the healthcare insurance and technology sectors. This high beta suggests that price swings will be amplified during periods of market stress, which is a critical factor for risk-averse investors analyzing the asset's risk-adjusted return profile.
Growth & Income
The company achieved a revenue growth of 17.3% year-over-year, while earnings growth is N/A due to the absence of positive net income in the trailing period. The divergence between strong revenue expansion and the inability to generate positive earnings growth implies that the company is prioritizing top-line acquisition and market share expansion over immediate profitability, a strategy common in the initial phases of scaling a digital health business. As a non-dividend payer, the company does not distribute dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning all generated cash flow is retained within the business to fund technology development and operational scaling. The overall growth and income profile is characterized by aggressive revenue expansion coupled with a complete reinvestment of cash flows, resulting in no current income distribution for shareholders but potential for future earnings realization as operating leverage improves.